INO · Insider Trading
Inovio Pharmaceuticals, Inc.
Every open-market purchase and sale reported by INO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-21 | Peter Kies | CFO | MIXED | +4,012 | −$5.77K |
| 2026-05-21 | Wendy L Yarno | Director | A | +76,000 deriv. | — |
| 2026-05-21 | Simon X Benito | Director | A | +76,000 deriv. | — |
| 2026-05-21 | Lota S. Zoth | Director | A | +76,000 deriv. | — |
| 2026-05-21 | Roger D Dansey | Director | A | +76,000 deriv. | — |
| 2026-05-21 | Michael John Sumner | Chief Medical Officer | MIXED | +6,757 | −$3.31K |
| 2026-05-21 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | +15,990 | −$15.14K |
| 2026-05-21 | Laurent Humeau | Chief Scientific Officer | MIXED | +3,864 | −$2.66K |
| 2026-05-21 | Jay Shepard | Director | A | +76,000 deriv. | — |
| 2026-05-21 | Ann Calby Miller | Director | A | +76,000 deriv. | — |
| 2026-05-21 | David B. Weiner | Director | A | +76,000 deriv. | — |
| 2026-05-18 | Laurent Humeau | Chief Scientific Officer | MIXED | +3,059 | −$2.23K |
| 2026-05-18 | Peter Kies | CFO | MIXED | +2,200 | −$3.34K |
| 2026-05-18 | Michael John Sumner | Chief Medical Officer | MIXED | +1,705 | −$884 |
| 2026-05-18 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | +10,027 | −$10.03K |
| 2026-04-01 | Michael John Sumner | Chief Medical Officer | MIXED | +3,069 | −$2.13K |
| 2026-03-05 | Michael John Sumner | Chief Medical Officer | A | +66,440 deriv. | — |
| 2026-03-05 | Laurent Humeau | Chief Scientific Officer | A | +48,400 deriv. | — |
| 2026-03-05 | Jacqueline Elizabeth Shea | Chief Executive Officer | A | +176,000 deriv. | — |
| 2026-03-05 | Peter Kies | CFO | A | +56,760 deriv. | — |
| 2026-02-27 | Laurent Humeau | Chief Scientific Officer | MIXED | +7,278 | −$9.13K |
| 2026-02-27 | Peter Kies | CFO | MIXED | +6,385 | −$16.57K |
| 2026-02-27 | David B. Weiner | Director | M | +972 | — |
| 2026-02-27 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | +25,319 | −$38.87K |
| 2026-02-27 | Michael John Sumner | Chief Medical Officer | MIXED | +12,657 | −$6.99K |
| 2025-07-01 | Michael John Sumner | Chief Medical Officer | M | +2,916 | — |
| 2025-05-21 | Wendy L Yarno | Director | M | +2,167 | — |
| 2025-05-21 | Lota S. Zoth | Director | M | +2,167 | — |
| 2025-05-21 | David B. Weiner | Director | M | +2,167 | — |
| 2025-05-21 | Jacqueline Elizabeth Shea | Chief Executive Officer | A | +190,150 deriv. | — |
| 2025-05-21 | Simon X Benito | Director | M | +2,167 | — |
| 2025-05-21 | Laurent Humeau | Chief Scientific Officer | A | +40,500 deriv. | — |
| 2025-05-21 | Jay Shepard | Director | M | +2,167 | — |
| 2025-05-21 | Michael John Sumner | Chief Medical Officer | A | +63,450 deriv. | — |
| 2025-05-21 | Ann Calby Miller | Director | M | +2,167 | — |
| 2025-05-21 | Peter Kies | CFO | A | +58,050 deriv. | — |
| 2025-05-21 | Roger D Dansey | Director | M | +2,167 | — |
| 2025-05-16 | Michael John Sumner | Chief Medical Officer | MIXED | +1,705 | −$1.33K |
| 2025-05-16 | Peter Kies | CFO | MIXED | +2,205 | −$5.00K |
| 2025-05-16 | Laurent Humeau | Chief Scientific Officer | MIXED | +3,063 | −$3.33K |
| 2025-05-16 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | +10,027 | −$15.05K |
| 2025-05-12 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | +3,108 | −$4.31K |
| 2025-02-28 | David B. Weiner | Director | M | +1,944 | — |
| 2025-02-28 | Laurent Humeau | Chief Scientific Officer | MIXED | +5,222 | −$7.21K |
| 2025-02-28 | Jacqueline Elizabeth Shea | Chief Executive Officer | MIXED | +12,903 | −$22.93K |
| 2025-02-28 | Michael John Sumner | Chief Medical Officer | M | +5,010 | — |
| 2025-02-28 | Peter Kies | CFO | MIXED | +3,685 | −$10.54K |
| 2024-12-18 | Michael John Sumner | Chief Medical Officer | A | +10,000 deriv. | — |
| 2024-07-01 | Michael John Sumner | Chief Medical Officer | M | +2,917 | — |
| 2024-05-22 | Simon X Benito | Director | A | +5,084 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jacqueline Elizabeth Shea | Chief Executive Officer | 123,327 | $107.27K |
| David B. Weiner | Director | 87,592 | $76.19K |
| Laurent Humeau | Chief Scientific Officer | 48,986 | $42.61K |
| Michael John Sumner | Chief Medical Officer | 44,731 | $38.91K |
| Peter Kies | CFO | 43,229 | $37.60K |
| Simon X Benito | Director | 12,191 | $10.60K |
| Wendy L Yarno | Director | 10,512 | $9.14K |
| Ann Calby Miller | Director | 9,877 | $8.59K |
| Jay Shepard | Director | 9,209 | $8.01K |
| Roger D Dansey | Director | 8,916 | $7.76K |
| Lota S. Zoth | Director | 8,726 | $7.59K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.